Risk-Reducing Mastectomy

Policy #: 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

Applicable to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (BRCA1 or BRCA2) is addressed separately in medical policy 00047.

Note: Genetic Cancer Susceptibility Panels Using Next Generation Sequencing is addressed separately in medical policy 00382.

Note: Moderate Penetrance Variants Associated With Breast Cancer in Individuals at High Risk Breast Risk is addressed separately in medical policy 00504.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider risk-reducing mastectomy in patients without breast cancer who are at high risk of breast cancer to be eligible for coverage.

Patient Selection Criteria:
Coverage eligibility will be considered for risk-reducing mastectomy in patients without breast cancer who are at high risk of breast cancer when ANY of the following criteria are met:
- A known BRCA1 or BRCA2 pathogenic or likely pathogenic gene variant; OR
- Another pathogenic or likely pathogenic gene variant associated with high breast cancer risk, i.e., TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), CDH1, STK11 and PALB2; OR
- High risk (lifetime risk 20% or greater) of developing breast cancer as identified by models that are largely defined by family history, i.e. National Cancer Institute Breast Cancer Risk...
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

Assessment Tool (also called the Gail model), or the Breast Cancer Surveillance Consortium (BCSC) Risk Calculator; OR

• Received radiation therapy to the chest between the ages of 10 and 30 years.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers risk-reducing mastectomy in patients without breast cancer for all other indications to be investigational.*

Note:
This medical policy and criteria are not applicable to contralateral risk-reducing mastectomy in women following a breast cancer diagnosis. Treating physicians shall consider recognized, evidence-based standards such as those by the National Comprehensive Cancer Network in making recommendations. Decisions regarding treatment procedures following a breast cancer diagnosis are to be made by the patient and treating physician.

Policy Guidelines

It is strongly recommended that all candidates for risk-reducing mastectomy undergo counseling regarding cancer risks from a health professional other than the operating surgeon skilled to assess cancer risk and to discuss various treatment options, including increased surveillance or chemoprevention with tamoxifen or raloxifene.

There is no standardized method for determining an individual's risk of breast cancer that incorporates all possible risk factors. There are validated risk prediction models, but they are based primarily on family history.

Some known individual risk factors confer a high risk by themselves. The following list includes factors known to indicate a high risk of breast cancer:

• Lobular carcinoma in situ
• A known BRCA1 or BRCA2 variant
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

- Another gene variant associated with high risk, eg, TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), CDH1, STK11, and PALB2
- Received radiotherapy to the chest between 10 and 30 years of age.

A number of other factors may increase the risk of breast cancer but do not by themselves indicate high risk (generally considered to be a lifetime risk of ≥20%). It is possible that combinations of these factors may be indicative of high risk, but it is not possible to give quantitative estimates of risk. As a result, it may be necessary to individualize the estimate of risk by taking into account numerous risk factors. A number of risk factors, not individually indicating high risk, are included in the National Cancer Institute Breast Cancer Risk Assessment Tool, also called the Gail model.

Another breast cancer risk assessment tool, used in the Women Informed to Screen Depending on Measures of Risk trial, is the Breast Cancer Surveillance Consortium (BCSC) Risk Calculator (https://tools.bcsc-scc.org/bc5yearrisk/calculator.htm). The following information is used in that assessment tool:
- History of breast cancer, ductal carcinoma in situ, breast augmentation, or mastectomy
- Age/race/ethnicity
- Number of first-degree relatives (mother, sister, or daughter) diagnosed with breast cancer
- Prior breast biopsies (positive or negative)
- Breast Imaging Reporting and Data System (BI-RADS) breast density (radiologic assessment of breast tissue density by radiologists who interpret mammograms).

Background/Overview
Risk-reducing mastectomy may be considered in individuals thought to be at high-risk of developing breast cancer, either due to family history, presence of genetic variants (eg, BRCA1, BRCA2, PALB2), having received radiotherapy to the chest, or the presence of lesions associated with increased cancer risk such as lobular carcinoma in situ. Therefore, bilateral risk-reducing mastectomy may be performed to eliminate the risk of cancer arising elsewhere; chemoprevention and close surveillance are alternative risk-reduction strategies. Risk-reducing mastectomies are typically bilateral but can also describe a unilateral mastectomy in a patient who has previously undergone or is currently undergoing a mastectomy in the opposite breast for invasive cancer (ie, contralateral risk-reducing mastectomy). Use of contralateral risk-reducing mastectomy has increased in the U.S. An analysis of data from the National Cancer Database found that the rate of contralateral risk-reducing mastectomy...
Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Risk-reducing mastectomy is defined as the removal of the breast in the absence of malignant disease to reduce the risk of breast cancer occurrence.
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

Summary of Evidence
For individuals who have a high-risk of breast cancer or extensive mammographic abnormalities precluding excision or biopsy who receive a risk-reducing mastectomy, the evidence includes systematic reviews. Relevant outcomes are overall survival (OS), disease-specific survival, functional outcomes, and treatment-related morbidity. Studies have found that a risk-reducing mastectomy lowers subsequent breast cancer incidence and increases survival in select high-risk patients. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unilateral breast cancer but are not otherwise at high-risk who receive a contralateral risk-reducing mastectomy, the evidence includes systematic reviews and observational studies. Relevant outcomes are OS, disease-specific survival, functional outcomes, and treatment-related morbidity. Available studies do not demonstrate a consistent survival benefit in individuals without high-risk criteria. Moreover, there are risks associated with a contralateral risk-reducing mastectomy for both the primary surgical and reconstruction procedures. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2016 Input
In response to requests, input was received from 1 specialty society and 6 academic medical centers while this policy was under review in 2016. Input addressed the use of contralateral prophylactic (risk-reducing) mastectomy in women with unilateral breast cancer who are not otherwise at high-risk for developing breast cancer in the contralateral breast. The input was mixed. Clinicians offered suggestions for modifying high-risk criteria but there was no consensus on potential additional risk factors.
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology
In 2020, the American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology published joint guidelines on management of hereditary breast cancer. The guideline discusses management of patients with breast cancer with germline mutations in breast cancer susceptibility genes (eg, BRCA1/2, ATM, TP53) and makes the following recommendations regarding risk-reducing mastectomy:

"Surgical management of the index malignancy (…contralateral risk-reducing mastectomy [CRRM]) in BRCA1/2 mutation carriers should be discussed, considering the increased risk of CBC [contralateral breast cancer] and possible increased risk of an ipsilateral new primary breast cancer compared with noncarriers (Type: formal consensus; Evidence quality: intermediate; Strength of recommendation: strong)."

"For women with breast cancer who have a BRCA1/2 mutation and who have been treated or are being treated with unilateral mastectomy, CRRM should be offered. CRRM is associated with a decreased risk of CBC; there is insufficient evidence for improved survival."

"Decisions regarding risk-reducing mastectomy (bilateral or contralateral) are highly personal and must be individualized for every patient. Studies show that women who opt for prophylactic mastectomy report positive outcomes, including decreased concern about developing breast cancer. This benefit must be weighed against possible problems with implants or reconstructive therapy and potential adverse feelings related to body image, femininity, and sexuality. Most patients who opt for prophylactic mastectomy demonstrate satisfaction with their decision."

"For women with breast cancer who have a mutation in a moderate-penetrance breast cancer predisposition gene and who have been treated or are being treated with unilateral mastectomy,
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

The decision regarding [contralateral risk-reducing mastectomy] CRRM should not be based predominantly on mutation status. Additional factors that predict CBC such as age at diagnosis and family history should be considered, as they are in all cases. The impact of CRRM on decreasing risk of CBC is dependent on the risk of CBC for each individual gene. Data regarding the risk of CBC resulting from moderate-penetrance genes are limited (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate)."

The guideline also provides recommendations for assessing the risk of CBC and role of risk-reducing mastectomy in BRCA1/2 mutation carriers (Evidence quality: low; Strength of recommendation: moderate) and in women with breast cancer who have a BRCA1/2 mutation who have been treated or are being treated with unilateral mastectomy when considering contralateral risk-reducing mastectomy (Evidence quality: intermediate; Strength of recommendation: moderate). The guideline recommends consideration of the following:

- Age at diagnosis (the strongest predictor of future CBC)
- Family history of breast cancer
- Overall prognosis from this or other cancers (eg, ovarian)
- Ability of patient to undergo appropriate breast surveillance (magnetic resonance imaging [MRI])
- Comorbidities
- Life expectancy.

Society of Surgical Oncology
In 2017, the Society of Surgical Oncology updated its position statement on risk-reducing mastectomy. The position statement concluded the following about risk-reducing mastectomy:

"There is no single-risk threshold above which risk-reducing mastectomy is clearly indicated, and it is important for treating physicians and surgeons to explain to individuals not only the risk assessment but also all available treatment strategies to facilitate a shared decision-making process."

"The available data suggest that BMP [bilateral prophylactic mastectomy] confers a survival advantage in women with the highest risk who undergo the procedure at a relatively early age …"
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

the impact of CPM [contralateral prophylactic mastectomy] in women with invasive breast cancer is more difficult to assess … however, CPM does not appear to confer a survival advantage."

National Cancer Institute
In 2013, the National Cancer Institute updated its fact sheet on risk-reducing surgery for breast cancer. The fact sheet stated women with the following characteristics may consider bilateral risk-reducing mastectomy:

- Deleterious variant in BRCA1 or BRCA2
- Strong family history of breast cancer
- Lobular carcinoma in situ and family history of breast cancer
- Radiotherapy to the chest before the age of 50 years.

Considering contralateral risk-reducing mastectomy, the Institute stated:
"Given that most women with breast cancer have a low risk of developing the disease in their contralateral breast, women who are not known to be at a very high risk but who remain concerned about cancer development in their other breast may want to consider options other than surgery to further reduce their risk of a contralateral breast cancer."

American Society of Breast Surgeons
In 2016, a consensus statement from the American Society of Breast Surgeons made the following recommendations on contralateral risk-reducing mastectomy:

"CPM [contralateral prophylactic mastectomy] should be considered for those at significant risk of CBC [contralateral breast cancer]
- Documented BRCA1/2 carrier
- Strong family history, but patient has not undergone genetic testing
- History of mantle chest radiation before age 30 years.

CPM can be considered for those at lower risk of CBC
- Gene carrier of... CHEK-2, PALB2, p53, CDH1
- Strong family history, patient BRCA negative, no known BRCA family member.

CPM may be considered for other reasons
- To limit contralateral breast surveillance (dense breasts, failed surveillance, recall fatigue)
- To improve reconstructed breast symmetry
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

- To manage risk aversion … [or] extreme anxiety." (note: anxiety may be better managed through psychological support strategies.)

CPM should be discouraged
- Average-risk women with unilateral breast cancer
- Women with advanced index cancer
- Women at high risk for surgical complications (e.g.,...comorbidities, obesity, smoker, diabetes)
- *BRCA* negative with a family of *BRCA*-positive carriers
- Male breast cancer, including *BRCA* carriers.

National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) has made recommendations on several cancers relevant to this evidence review. On breast cancer risk-reduction (v. 1.2022), the NCCN recommends:

"Risk-reducing mastectomy should generally be considered only in women with a pathogenic/likely pathogenic genetic mutation (not variants of undetermined significance) conferring a high risk for breast cancer..., compelling family history, or possibly with prior thoracic RT [radiation therapy] at <30 years of age. The value of risk-reducing mastectomy in individuals with pathogenic/likely pathogenic mutations in other genes associated with a 2-fold or greater risk for breast cancer … in the absence of a compelling family history of breast cancer is unknown."

For invasive breast cancer (v. 3.2022) the NCCN has discouraged contralateral risk-reducing mastectomy, except for certain high-risk situations (noted in the risk-reduction guideline previously discussed). The guidelines state:
"....risk reduction mastectomy of a breast contralateral to a known unilateral breast cancer treated with mastectomy or breast-conserving therapy is discouraged by the panel."

As part of a genetic/familial high-risk assessment for breast, ovarian, and pancreatic cancer (v. 1.2023), the NCCN recommends that the option of risk-reduction mastectomy (RRM) be discussed in women with *BRCA*-related breast and/or ovarian syndrome, Li-Fraumeni syndrome (TP53), Cowden syndrome or PTEN hamartoma tumor syndrome, CDH1, PALB2, or STK11 germline pathogenic or likely pathogenic variants. In addition, the NCCN guidelines note that evidence is insufficient for
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

RRM and recommend that risk-reducing mastectomy be considered based on family history in women with certain genetic variants including ATM, BARD1, CHEK2, and NF1.

American College of Genetics and Genomics
In 2021, the American College of Genetics and Genomics published a guideline on management of individuals with PALB2 variants, which recommends that risk-reducing mastectomy be considered as an option based on personal risk.

U.S. Preventive Services Task Force Recommendations
No U.S. Preventive Services Task Force recommendations for prophylactic mastectomy have been identified.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in June 2022 did not identify any ongoing or unpublished trials that would likely influence this review.

References

©2022 Blue Cross and Blue Shield of Louisiana
Risk-Reducing Mastectomy

Policy #  00141
Original Effective Date:  09/27/2004
Current Effective Date:  11/14/2022


©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022


Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022


Policy History
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

08/31/2004 Medical Director review
09/21/2004 Medical Policy Committee review
09/27/2004 Managed Care Advisory Council approval
09/07/2005 Medical Director review
09/20/2005 Medical Policy Committee review
Coverage eligibility unchanged
09/22/2005 Quality Care Advisory Council approval
07/07/2006 Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
10/04/2006 Medical Director review
10/18/2006 Medical Policy Committee approval. Policy statement unchanged. Addition of FDA and or other governmental regulatory approval. References added.
10/10/2007 Medical Director review
10/17/2007 Medical Policy Committee approval. No change to coverage eligibility.
10/01/2008 Medical Director review
10/22/2008 Medical Policy Committee approval. No change to coverage eligibility.
10/01/2009 Medical Policy Committee approval
10/14/2009 Medical Policy Implementation Committee approval. Added moderately increased risk for breast cancer to be eligible for coverage with criteria. Added last two criteria bullets for high risk breast cancer.
10/14/2010 Medical Policy Committee review
10/06/2011 Medical Policy Committee review
Risk-Reducing Mastectomy

Policy #  00141
Original Effective Date:  09/27/2004
Current Effective Date:  11/14/2022

10/11/2012  Medical Policy Committee review
10/31/2012  Medical Policy Implementation Committee approval. The term “p53” was updated to the more current “TP53” terminology in the Patient Selection Criteria.
10/03/2013  Medical Policy Committee review
10/16/2013  Medical Policy Implementation Committee approval. High risk criteria revised to track BCBSA. Investigational statement reworded to track BCBSA.
10/02/2014  Medical Policy Committee review
08/03/2015  Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/08/2015  Medical Policy Committee review
10/21/2015  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/06/2016  Medical Policy Committee review
10/19/2016  Medical Policy Implementation Committee approval. Removed coverage statement on lobular carcinoma in situ and added LCIS to criteria for high risk. CDH1, or STK11 mutation added to high risk criteria. Removed moderate risk from policy statement and a coverage statement for extensive abnormalities.
01/01/2017  Coding update: Removing ICD-9 Diagnosis Codes
10/05/2017  Medical Policy Committee review
10/18/2017  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/04/2018  Medical Policy Committee review
10/17/2018  Medical Policy Implementation Committee approval. Title changed from “Prophylactic Mastectomy” to “Risk-Reducing Mastectomy”. “Prophylactic” mastectomy changed to “risk-reducing” mastectomy throughout the policy to reflect preferred terminology in the literature and by NCCN. Added examples of the National Cancer Institute Breast Cancer Risk Assessment Tool (also called the Gail model), or the Breast Cancer Surveillance Consortium (BCSC) Risk Calculator to the 4th criteria bullet for risk-reducing mastectomy in patients at high risk of breast cancer. Deleted the “When Services Are Eligible for Coverage” section. Added the Policy Guidelines section from BCBSA’s policy. Removed references to “extensive mammographic abnormalities” throughout the policy.
Risk-Reducing Mastectomy

Policy # 00141
Original Effective Date: 09/27/2004
Current Effective Date: 11/14/2022

10/01/2020 Medical Policy Committee review
10/07/2020 Medical Policy Implementation Committee approval. Added the specification of patients without breast cancer to the eligible for coverage and investigational statements. Removed lobular carcinoma in situ (LCIS) from the Patient Selection Criteria. Removed “including but not limited to contralateral risk reducing mastectomy in women with breast cancer who do not meet risk criteria” from the investigational statement. A Note was added at the end of the coverage section with specific language from the HB 347 to reinforce that evidence-based standards (e.g. NCCN) are to be considered and decisions are to be made by the patient and treating provider.

10/07/2021 Medical Policy Committee review

10/06/2022 Medical Policy Committee review
10/11/2022 Medical Policy Implementation Committee approval. Added “pathogenic or likely pathogenic gene” to describe variants in the eligible for coverage criteria. Added PALB2 to the eligible for coverage criteria list of gene variants for risk-reducing mastectomy in patients without breast cancer who are at high risk of breast cancer.

Next Scheduled Review Date: 10/2023

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and are not part of the Blue Cross and Blue Shield of Louisiana Medical Policy Coverage Guidelines.
Risk-Reducing Mastectomy

Policy #  00141
Original Effective Date:  09/27/2004
Current Effective Date:  11/14/2022

the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>19301, 19302, 19303, 19305, 19306, 19307</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>D05.00-D05.92, Z15.01, Z40.01, Z80.3</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Risk-Reducing Mastectomy

Policy #  00141  
Original Effective Date:  09/27/2004  
Current Effective Date:  11/14/2022

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.